AR052346A1 - Composicion que comprende una epotilona y metodos para producir dicha composicion - Google Patents
Composicion que comprende una epotilona y metodos para producir dicha composicionInfo
- Publication number
- AR052346A1 AR052346A1 ARP050105469A ARP050105469A AR052346A1 AR 052346 A1 AR052346 A1 AR 052346A1 AR P050105469 A ARP050105469 A AR P050105469A AR P050105469 A ARP050105469 A AR P050105469A AR 052346 A1 AR052346 A1 AR 052346A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- methods
- epotilone
- produce
- epothilones
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Silicon Polymers (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Métodos para producir formulaciones farmacéuticas de epotilonas apropiadas para administrar por vía parenteral, tal como por vía intravenosa. Composicion farmacéutica, método para tratar el cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04090516A EP1674098A1 (en) | 2004-12-23 | 2004-12-23 | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052346A1 true AR052346A1 (es) | 2007-03-14 |
Family
ID=34928859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105469A AR052346A1 (es) | 2004-12-23 | 2005-12-22 | Composicion que comprende una epotilona y metodos para producir dicha composicion |
Country Status (23)
Country | Link |
---|---|
EP (3) | EP1674098A1 (es) |
JP (1) | JP2008525362A (es) |
KR (1) | KR20070088802A (es) |
CN (1) | CN101137364B (es) |
AR (1) | AR052346A1 (es) |
AU (1) | AU2005318353B2 (es) |
BR (1) | BRPI0519441A2 (es) |
CA (1) | CA2591997A1 (es) |
CR (1) | CR9211A (es) |
GT (1) | GT200500386A (es) |
HK (1) | HK1114015A1 (es) |
IL (1) | IL183937A0 (es) |
MX (1) | MX2007007780A (es) |
NO (1) | NO20073772L (es) |
NZ (1) | NZ555989A (es) |
PA (1) | PA8657901A1 (es) |
PE (2) | PE20100240A1 (es) |
RU (1) | RU2416407C2 (es) |
SG (1) | SG161207A1 (es) |
TW (1) | TWI367758B (es) |
UA (1) | UA88182C2 (es) |
UY (1) | UY29307A1 (es) |
WO (1) | WO2006066949A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
RS63747B1 (sr) | 2011-04-28 | 2022-12-30 | Oncopeptides Ab | Liofilizovani preparat citotoksičnih dipeptida |
EP2928463B1 (en) | 2012-10-26 | 2019-11-20 | Oncopeptides AB | Lyophilized preparations of melphalan flufenamide |
CN107041886A (zh) | 2016-02-06 | 2017-08-15 | 北京华昊中天生物技术有限公司 | 脱环氧埃坡霉素衍生物制剂、制备及其***的应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
DE19728914A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Metallisch gefärbte Polyamide |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
DK1005465T3 (da) | 1997-08-09 | 2007-11-05 | Bayer Schering Pharma Ag | Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
CZ303168B6 (cs) * | 1998-02-05 | 2012-05-09 | Novartis Ag | Farmaceutický prostredek |
DE19820599A1 (de) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung |
WO1999067253A2 (en) | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
SE517641C2 (sv) | 1998-07-02 | 2002-07-02 | Sca Hygiene Prod Ab | Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar |
ATE248175T1 (de) | 1998-12-22 | 2003-09-15 | Novartis Pharma Gmbh | Epothilonderivate und ihre verwendung als antitumormittel |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
DE19908760A1 (de) | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
HUP0105478A3 (en) | 1999-02-18 | 2002-08-28 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
DE19908763A1 (de) | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
DE19907588A1 (de) | 1999-02-22 | 2000-08-24 | Biotechnolog Forschung Gmbh | C-21 Modifizierte Epothilone |
US20020058286A1 (en) | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
IL144590A0 (en) * | 1999-03-29 | 2002-05-23 | Bristol Myers Squibb Co | A process for the preparation of epothilone derivatives |
AR023792A1 (es) * | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
JP2004500388A (ja) | 2000-03-01 | 2004-01-08 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロン、その中間体およびその類似体の合成 |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
DE10020517A1 (de) | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
US20020045609A1 (en) | 2000-05-26 | 2002-04-18 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
US20020052028A1 (en) | 2000-08-09 | 2002-05-02 | Daniel Santi | Bio-intermediates for use in the chemical synthesis of polyketides |
US20020137152A1 (en) | 2000-07-25 | 2002-09-26 | Daniel Santi | Fermentation process for epothilones |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
EP1414384A4 (en) | 2000-10-13 | 2005-07-27 | Univ Mississippi | SYNTHESIS OF EPOTHILONES AND RELATED ANALOGS |
AU2002221693A1 (en) | 2000-10-16 | 2002-04-29 | Morphochem Ag | Epothilone synthesis components iii and iv: asymmetrically substituted acyloins and acyloin derivatives, method for the production thereof and method for the production of epithilone b, d and epothilone derivatives |
BR0206511A (pt) * | 2001-01-25 | 2003-10-21 | Bristol Myeres Squibb Company | Formulação parenteral para análogos de epotilona |
CZ20032021A3 (cs) * | 2001-01-25 | 2004-05-12 | Bristol@Myersásquibbácompany | Způsoby podávání analogů epothilonu při léčbě rakoviny |
MXPA03006412A (es) * | 2001-01-25 | 2003-10-15 | Bristol Myers Squibb Co | Metodos para administrar analogos de epotilona para tratamiento de cancer. |
EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
AU2003279911A1 (en) * | 2002-10-09 | 2004-05-04 | Kosan Biosciences, Inc. | Therapeutic formulations |
EP1670487A4 (en) * | 2003-10-09 | 2008-05-21 | Kosan Biosciences Inc | THERAPEUTIC FORMULATIONS |
US20080171687A1 (en) * | 2004-09-16 | 2008-07-17 | Abraxis Bioscience, Inc. | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs |
-
2004
- 2004-12-23 EP EP04090516A patent/EP1674098A1/en not_active Withdrawn
-
2005
- 2005-12-20 CA CA002591997A patent/CA2591997A1/en not_active Abandoned
- 2005-12-20 MX MX2007007780A patent/MX2007007780A/es active IP Right Grant
- 2005-12-20 EP EP05823451A patent/EP1827428A1/en not_active Withdrawn
- 2005-12-20 AU AU2005318353A patent/AU2005318353B2/en not_active Ceased
- 2005-12-20 CN CN2005800486324A patent/CN101137364B/zh not_active Expired - Fee Related
- 2005-12-20 NZ NZ555989A patent/NZ555989A/en not_active IP Right Cessation
- 2005-12-20 EP EP10178620A patent/EP2371365A1/en not_active Withdrawn
- 2005-12-20 RU RU2007128068/15A patent/RU2416407C2/ru not_active IP Right Cessation
- 2005-12-20 UA UAA200708381A patent/UA88182C2/ru unknown
- 2005-12-20 JP JP2007547378A patent/JP2008525362A/ja not_active Ceased
- 2005-12-20 KR KR1020077016710A patent/KR20070088802A/ko not_active Application Discontinuation
- 2005-12-20 BR BRPI0519441-5A patent/BRPI0519441A2/pt not_active IP Right Cessation
- 2005-12-20 WO PCT/EP2005/013942 patent/WO2006066949A1/en active Application Filing
- 2005-12-20 SG SG201001967-7A patent/SG161207A1/en unknown
- 2005-12-22 AR ARP050105469A patent/AR052346A1/es unknown
- 2005-12-22 GT GT200500386A patent/GT200500386A/es unknown
- 2005-12-22 PA PA20058657901A patent/PA8657901A1/es unknown
- 2005-12-22 UY UY29307A patent/UY29307A1/es not_active Application Discontinuation
- 2005-12-23 TW TW094146404A patent/TWI367758B/zh not_active IP Right Cessation
-
2006
- 2006-01-03 PE PE2010000026A patent/PE20100240A1/es not_active Application Discontinuation
- 2006-01-03 PE PE2006000008A patent/PE20060839A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183937A patent/IL183937A0/en unknown
- 2007-06-26 CR CR9211A patent/CR9211A/es not_active Application Discontinuation
- 2007-07-19 NO NO20073772A patent/NO20073772L/no not_active Application Discontinuation
-
2008
- 2008-08-22 HK HK08109400.7A patent/HK1114015A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101137364A (zh) | 2008-03-05 |
NZ555989A (en) | 2010-12-24 |
CN101137364B (zh) | 2011-11-16 |
EP2371365A1 (en) | 2011-10-05 |
BRPI0519441A2 (pt) | 2009-01-20 |
IL183937A0 (en) | 2007-10-31 |
NO20073772L (no) | 2007-09-21 |
MX2007007780A (es) | 2007-08-14 |
TWI367758B (en) | 2012-07-11 |
CA2591997A1 (en) | 2006-06-29 |
EP1827428A1 (en) | 2007-09-05 |
GT200500386A (es) | 2006-08-01 |
RU2007128068A (ru) | 2009-01-27 |
UY29307A1 (es) | 2006-07-31 |
PE20100240A1 (es) | 2010-05-02 |
EP1674098A1 (en) | 2006-06-28 |
PA8657901A1 (es) | 2007-01-17 |
KR20070088802A (ko) | 2007-08-29 |
HK1114015A1 (en) | 2008-10-24 |
SG161207A1 (en) | 2010-05-27 |
RU2416407C2 (ru) | 2011-04-20 |
AU2005318353A1 (en) | 2006-06-29 |
AU2005318353B2 (en) | 2011-09-29 |
PE20060839A1 (es) | 2006-09-15 |
UA88182C2 (ru) | 2009-09-25 |
TW200635586A (en) | 2006-10-16 |
CR9211A (es) | 2007-11-23 |
WO2006066949A1 (en) | 2006-06-29 |
JP2008525362A (ja) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000957A1 (es) | Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer. | |
CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
BR112016004023A2 (pt) | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto | |
CR20120625A (es) | Métodos de tratamiento contra el cáncer pancreático | |
ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
ECSP109934A (es) | Compuesto - 946 | |
GT200800158A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
MX2010002179A (es) | Composicion para el tratamiento de enfermedades neoplasicas. | |
MX363189B (es) | Productos químicos, composiciones y métodos para tratamiento y prevención de infecciones de virus orthopox y enfermedades asociadas. | |
CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
CU24349B1 (es) | Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer | |
GT200500113A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
UY30220A1 (es) | Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo | |
CR9558A (es) | Formulaciones de quinina | |
CL2008002394A1 (es) | Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos. | |
NI201000031A (es) | Derivados de ciclopropilamida. | |
CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
CU24052B1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos | |
UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
EP2061456A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME | |
AR052346A1 (es) | Composicion que comprende una epotilona y metodos para producir dicha composicion | |
MA32588B1 (fr) | Derives azotes de la pancratistatine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |